Y-mAbs Therapeutics, Inc.: cashflow_financing
| Value | {"amount": 108214000, "concept": "us-gaap:NetCashProvidedByUsedInFinancingActivities", "currency": "USD"} |
|---|---|
| Period | 2021-01-01 – 2021-09-30 |
| Status | current |
| Entity | Y-mAbs Therapeutics, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T17:37:23.958445+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/0dd11be7-759f-4076-bc91-cf8f6520fed3
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001558370-21-014548Retrieved: 2026-08-19T17:37:23.958445+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001722964/cashflow-financing/2021-09-30 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/0dd11be7-759f-4076-bc91-cf8f6520fed3
History
- no predecessors — first report